Kinnate Biopharma’s $276 Million IPO


Wilson Sonsini Goodrich & Rosati advised Kinnate Biopharma Inc. on the deal.

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of its initial public offering, raising $276 million. The shares began trading on The Nasdaq Global Select Market on December 3, 2020, under the symbol “KNTE.” All shares were offered by Kinnate.

A Wilson Sonsini Goodrich & Rosati team, which includes Miranda Biven (Picture), Tony Jeffries, Jennifer Knapp, and Lance Brady represented Kinnate Biopharma in the transaction.

Involved fees earner: Miranda Biven – Wilson Sonsini Goodrich & Rosati; Lance Brady – Wilson Sonsini Goodrich & Rosati; Tony Jeffries – Wilson Sonsini Goodrich & Rosati; Jennifer Knapp – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Kinnate Biopharma Inc;

Avatar

Author: Ambrogio Visconti